GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Valneva SE (NAS:VALN) » Definitions » Cash And Cash Equivalents

Valneva SE (Valneva SE) Cash And Cash Equivalents

: $137.5 Mil (As of Dec. 2023)
View and export this data going back to 2021. Start your Free Trial

Valneva SE's quarterly cash and cash equivalents declined from Jun. 2023 ($221.46 Mil) to Sep. 2023 ($182.77 Mil) but then stayed the same from Sep. 2023 ($182.77 Mil) to Dec. 2023 ($137.49 Mil).

Valneva SE's annual cash and cash equivalents declined from Dec. 2021 ($391.69 Mil) to Dec. 2022 ($303.53 Mil) and declined from Dec. 2022 ($303.53 Mil) to Dec. 2023 ($137.49 Mil).

Valneva SE Cash And Cash Equivalents Historical Data

The historical data trend for Valneva SE's Cash And Cash Equivalents can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Valneva SE Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Cash And Cash Equivalents
Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 71.60 248.66 391.69 303.53 137.49

Valneva SE Quarterly Data
Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
Cash And Cash Equivalents Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 303.53 272.47 221.46 182.77 137.49

Valneva SE Cash And Cash Equivalents Calculation

Cash and cash equivalents are the most liquid assets on the balance sheet. Cash equivalents are assets that are readily convertible into cash, such as money market holdings, short-term government bonds or Treasury bills, marketable securities and commercial paper.

Valneva SE  (NAS:VALN) Cash And Cash Equivalents Explanation

A high number means either:

1) The company has competitive advantage generating lots of cash

2) Just sold a business or bonds (not necessarily good)

A low stockpile of cash usually means poor to mediocre economics.

There are 3 ways to create large cash reserve.

1) Sell new bonds or equity to public

2) Sell business or asset

3) It has an ongoing business generating more cash than it burns (usually means durable competitive advantage)

When a company is suffering a short term problem, Buffett looks at cash or marketable securities to see whether it has the financial strength to ride it out.

Important: Lots of cash and marketable securities + little debt = good chance that the business will sail on through tough times.

Test to see what is creating cash by looking at past 7 yrs of balance sheets. This will reveal how the cash was created.

Be Aware

Depreciation estimates make the calculation of net income susceptible to management's accounting choices. These choices can be either overly aggressive or overly conservative.

Valneva SE Cash And Cash Equivalents Related Terms

Thank you for viewing the detailed overview of Valneva SE's Cash And Cash Equivalents provided by GuruFocus.com. Please click on the following links to see related term pages.

Valneva SE (Valneva SE) Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Valneva SE (NAS:VALN) » Definitions » Cash And Cash Equivalents
Comparable Companies
XPAR:MEDCL XPAR:NANO XPAR:ALSEN XPAR:ALCLS XPAR:IPH XPAR:IVA XPAR:AELIS XPAR:ABVX XPAR:GNFT XPAR:DBV OCSE:NOVO B VRTX REGN ASX:CSL XKRX:207940 MRNA XKRX:068270 XBRU:ARGX XBRU:UCB BNTX
Traded in Other Exchanges
INRLF:USA VLA:France AYJ:Germany VLA:Austria
Address
6 Rue Alain Bombard, Saint-Herblain, FRA, 44800
Website
https://www.valneva.com
Valneva SE is a vaccine company focused on developing life-saving vaccines. Its portfolio includes two vaccines for travelers. The segments of the group are Commercialized vaccines which relate to marketed vaccines, the group's vaccines IXIARO/JESPECT, DUKORAL, & third-party products; Covid includes development, manufacturing, & distribution related to the COVID-19 vaccine, Vaccine candidates which relate to research and development programs to generate new approvable products to generate future cash flows from product sales through partnering with pharmaceutical companies; & Technologies and services which relate to services and inventions at a commercialization stage. The majority is from the Commercialized vaccines segment & geographically from the United States.